Related Experiment Video
Updated: Jul 20, 2025
08:47
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
9.8K
Glycogen synthase kinase-3: A potential target for diabetes
Divya M Teli1, Anuradha K Gajjar1
1Department of Pharmaceutical Chemistry and Quality Assurance, L. M. College of Pharmacy, Ahmedabad, Gujarat 380009, India.
Bioorganic & Medicinal Chemistry
|August 3, 2023
Summary
Glycogen synthase kinase-3 (GSK-3) inhibitors show promise for treating Type II diabetes by targeting glycogen metabolism. Research focuses on structural analysis and molecular modeling to develop effective anti-diabetic therapeutics.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- Elevated glucose levels due to beta-cell dysfunction are hallmarks of Type II diabetes.
- Glycogen synthase kinase-3 (GSK-3) plays a crucial role in regulating glycogen metabolism.
- GSK-3 inhibitors are being investigated for their potential anti-diabetic effects.
Purpose of the Study:
- To review structural analyses and molecular modeling of GSK-3.
- To explore the GSK-3 signaling pathway as a therapeutic target for diabetes.
- To discuss advancements in developing novel GSK-3 inhibitors for Type II diabetes.
Main Methods:
- Examination of structural data for GSK-3.
- Analysis of molecular modeling studies.
- Review of cellular biological investigations on GSK-3 regulation.
Main Results:
- Elucidation of GSK-3 regulatory mechanisms.
- Identification of structural features relevant for inhibitor design.
- Overview of molecular modification strategies for GSK-3 inhibitors.
Conclusions:
- GSK-3 is a viable therapeutic target for Type II diabetes.
- Structural and molecular modeling insights guide the development of GSK-3 inhibitors.
- Continued research on molecular modifications can lead to novel anti-diabetic drugs.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
01:15Hypoglycemia and Glucagon
301
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
301
01:22Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
01:16Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
01:25cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K